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Abstract
Background: There are few reports of the association of other cancers with Ewing 
sarcoma in patients and their relatives. We use a resource combining statewide gene-
alogy and cancer reporting to provide unbiased risks.
Methods: Using a combined genealogy of 2.3 million Utah individuals and the Utah 
Cancer Registry (UCR), relative risks (RRs) for cancers of other sites were estimated 
in 143 Ewing sarcoma patients using a Cox proportional hazards model with matched 
controls; however, risks in relatives were estimated using internal cohort‐specific 
cancer rates in first‐, second‐, and third‐degree relatives.
Results: Cancers of three sites (breast, brain, complex genotype/karyotype sarcoma) 
were observed in excess in Ewing sarcoma patients. No Ewing sarcoma patients 
were identified among first‐, second‐, or third‐degree relatives of Ewing sarcoma 
patients. Significantly increased risk for brain, lung/bronchus, female genital, and 
prostate cancer was observed in first‐degree relatives. Significantly increased risks 
were observed in second‐degree relatives for breast cancer, nonmelanoma eye cancer, 
malignant peripheral nerve sheath cancer, non‐Hodgkin lymphoma, and translocation 
sarcomas. Significantly increased risks for stomach cancer, prostate cancer, and acute 
lymphocytic leukemia were observed in third‐degree relatives.
Conclusions: This analysis of risk for cancer among Ewing sarcoma patients and 
their relatives indicates evidence for some increased cancer predisposition in this 
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1 |  INTRODUCTION
Ewing sarcoma is a rare tumor occurring most often in the 
bones or soft tissues of children and young adults. Ewing 
sarcoma accounts for ~1.5% of all childhood cancers and, al-
though uncommon, is still considered the second most com-
mon type of bone tumor in children. One common feature 
of Ewing sarcoma tumors is the presence of a translocation 
involving EWSR1 and a member of the E26 transformation‐ 
specific (ETS)  transcription factor family, most commonly 
FLI1 (about 85% of patients).1-4 Although the genetic epide-
miology of Ewing sarcoma is not entirely clear, race remains 
a known significant risk factor for Ewing sarcoma, with inci-
dence in Caucasians nine times greater than in Africans (0.155 
vs 0.017 per 105 individuals).5 Further supporting an element 
of genetic risk, despite an overall incidence of just one case 
per million, there are several reports of Ewing sarcoma ob-
served in siblings.6-9 Based on this evidence, genetic risk loci 
have been sought through multiple genome‐wide association 
study efforts, but there is no consensus as to what degree 
these risk candidates contribute to Ewing sarcoma develop-
ment.10-12 Other studies have investigated germline mutations 
in known cancer predisposition genes, finding a minority 
(11%) of patients to have pathogenic, or probably pathogenic, 
variants in TP53, RET, and PMS213; family history does not 
predict the presence of a syndrome in most patients. A patho-
genic role for these mutations in Ewing sarcoma has not been 
demonstrated.14 Specific environmental exposures have not 
been recognized as risk factors, although an association with 
the occupation of farming in parents has been suggested,15-18 
and hernias in childhood have been associated with increased 
risk19-21; this association with hernias is unclear but may indi-
cate common neuroectodermal pathways contributing to risk.
There have been few studies reporting the risk of other 
cancers in Ewing sarcoma patients or their relatives. Ji and 
Hemminki22 reported significantly increased risk for Ewing 
sarcoma (SIR = 16.5; 1.60, 60.8) when a sibling was diag-
nosed with Ewing sarcoma; in addition, a significantly in-
creased risk of Ewing sarcoma was observed for parental 
kidney cancer (SIR = 5.6 (1.5, 14.6). Novakovic23 reported 
no overall increased risk of cancer among 4628 first‐ or 
second‐degree relatives of 256 Ewing sarcoma patients; 
however, several specific tumor types were observed in sig-
nificant excess, including stomach cancer (RR  =  2.0; 1.4, 
2.8); melanoma (RR = 1.9; 1.2, 2.8); brain tumor (RR = 1.9; 
1.1, 3.0); and bone cancer (RR = 4.2; 1.7, 8.6). Risks of these 
cancers were higher among maternal than paternal relatives, 
but not significantly. Given Ewing sarcoma's rarity as well as 
the inaccuracies often associated with familial cancer ques-
tionnaires, unbiased identification of overrepresented cancers 
among relatives of Ewing sarcoma patients is challenging. 
Here we utilize a unique Utah population‐based resource to 
expand the characterization of risk for cancers of other sites 
in Ewing sarcoma patients and in their relatives.
2 |  MATERIALS AND METHODS
2.1 | Utah population database
The Utah Population Database (UPDB) includes a computer-
ized genealogy of the original Utah pioneers and their de-
scendants to modern day.24,25 The genealogical data have 
been linked to a statewide cancer registry from 1966, allow-
ing identification of all relationships among cancer patients. 
The genealogical data today extend to 16 generations. To en-
sure similarity with respect to membership in the population 
and record linking quality for all comparisons, analysis of 
data within the UPDB is limited here to individuals with at 
least three generations of genealogy data who link to origi-
nal Utah founders. In the UPDB data analyzed here, there 
are 2.3 million individuals with at least three generations of 
genealogy, and these individuals are linked to approximately 
123 000 Utah cancer records.
2.2 | Utah Ewing Sarcoma patients
The Utah Cancer Registry (UCR) was formed in 1966; in 
1973, it became one of the now 11 registries that make up 
the National Cancer Institute's Surveillance, Epidemiology, 
and End Results (SEER) program. Data are collected using 
a standardized set of definitions and codes. All cancers re-
ported to the UCR are manually consolidated and edited by 
certified tumor registrars. Data only for all independent pri-
mary cancers diagnosed or treated in Utah are collected and 
stored in the UCR, including primary site, histology, behav-
ior, age at diagnosis, stage, grade, survival, and treatment, 
among others; data on cancer recurrence are not reported or 
stored. Ewing sarcoma patients who linked to at least three 
generations of genealogy in the UPDB were identified from 
UCR records based on the International Classification of 
population which can be used to individualize consideration of potential treatment of 
patients and screening of patients and relatives.
K E Y W O R D S
cancer, Ewing sarcoma, relative, relative risk, UPDB
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Diseases for Oncology (ICD‐O) Revision 3 with histology 
9260 (n = 130), or 9364 (n = 13).
2.3 | Estimation of risk for cancer
To estimate relative risk (RR) among relatives of Ewing sar-
coma cancer patients for cancer, by site, the disease rate for 
each cancer site in the UPDB was estimated independently. 
The definitions for cancers analyzed are seen in Table S1 and 
include only primary site, histology, and behavior coding. 
Because cancer rates differ by sex, may change over time, 
and are generally lower in Utah, cohort‐specific cancer rates 
were estimated from individuals in the UPDB who have at 
least three generations of genealogy data. These individuals 
were assigned to a specific cohort that was determined by sex, 
year of birth (5 year cohorts), and birth state (Utah or not). 
Cohort‐specific rates for each cancer site were estimated by 
dividing the number of cancer patients in each cohort by the 
total number of individuals in each cohort. The RR for can-
cer of any site in a group of individuals was estimated as the 
ratio of the observed number of cancer patients for the site of 
interest to the expected number of cancer patients among the 
group of individuals. The observed number of cancer patients 
among the group of individuals was summed over all cohorts, 
the expected number of patients was calculated by multiplying 
the number of individuals in each cohort by the cohort‐specific 
rate of the cancer of interest, and summing over all cohorts. 
One‐sided P‐values indicating the probability of observing 
an excess number of a specific cancer were calculated under 
the assumption that the number of observed cancers follows 
a Poisson random variable with a mean equal to the expected 
number of cancers. This same RR estimation procedure was 
used for each cancer site, and for each set of relatives (first‐, 
second‐, and third‐degree).
Because individuals with Ewing sarcoma have a decreased 
life expectancy, their years at risk for developing cancer is 
lower than that of the general population; this decreased time at 
risk must be accounted for by modifying the estimation of risk 
for cancer. Therefore, in contrast to the estimation of cancer 
risk in relatives, to calculate RRs for cancer for the Ewing sar-
coma patients, each Ewing sarcoma case was matched, without 
replacement, to 100 cohort‐matched controls with appropriate 
genealogy data. A Cox proportional hazards model in R using 
the coxphf package was performed, and distinct survival func-
tions were fit, by cancer site, for Ewing sarcoma patients, and 
for controls. For each cancer site, the time to event was defined 
as the number of years (in 1‐year increments) it took for an in-
dividual to be diagnosed with the cancer of interest. Censoring 
occurred when individuals died without being diagnosed with 
a specific cancer. For each cancer site, the dependent variable 
“time to diagnosis” was modeled as being determined by an 
individual's Ewing sarcoma case status and UPDB cohort co-
variate profile. After fitting a Cox proportional hazards model, 
a hazard rate for the cancer of interest was determined for pa-
tients and for controls. The hazard ratio (HR) was calculated 
as the ratio of the case rate to the control rate, and signifies an 
Ewing sarcoma case's increased risk per 1‐year time period for 
developing a specific cancer. Risks for 38 different cancer sites 
for which there were at least 200 patients recorded in the UCR 
(Table S1) were estimated for Ewing sarcoma patients and for 
their first‐, second‐, and third‐degree relatives.
3 |  RESULTS
In the UCR, 143 individuals diagnosed with Ewing sarcoma 
were identified who had at least three generations of geneal-
ogy; 90 (63%) patients were male (average age of diagno-
sis 20.9 years ± 13.6; median age = 32 years) and 53 (37%) 
were female (average age of diagnosis 17.6  years  ±  11.3; 
median age = 10 years); 96 patients (67%) were no longer 
living and had an average age of death of 26.4 years ± 14.8. 
The remaining 47 patients had an average current age of 
33.7  years  ±  14.3. The 143 Ewing sarcoma patients had a 
total of 744 first‐degree relatives, 2228 second‐degree rela-
tives, and 6552 third‐degree relatives.
Cancers of four different primary cancer sites other than 
Ewing sarcoma (breast, brain, complex genotype/karyotype 
sarcoma, and unknown site) were observed in at least one 
Ewing sarcoma case. For those Ewing sarcoma patients where 
data were available for age at diagnosis for both cancers, 50% 
of the other cancers occurred at an average of 18 years after 
the diagnosis of Ewing sarcoma, and 50% of the other can-
cers occurred at an average of 2 years before the diagnosis 
of Ewing sarcoma. Table 1 summarizes HR estimates for the 
cancer sites that were observed to be significantly elevated in 
Ewing sarcoma patients. Due to the small sample sizes and to 
ensure confidentiality, no data on the sample sizes or charac-
teristics of the other cancers are provided.
Within the UPDB, Ewing sarcoma patients had a total of 
744 first‐degree, 2228 second‐degree, and 6,552 third‐degree 
relatives who also had at least three generations of genealogy 
data. RR estimates for cancers that were observed in signifi-
cant excess among first‐, second‐, and third‐degree relatives 
of the 143 Ewing Sarcoma patients are summarized in Table 2; 
T A B L E  1  Estimated hazard ratios for cancers observed in 
significant excess in the 143 individuals diagnosed with Ewing 
sarcoma
Cancer site P‐value Hazard ratio 95% CI
Brain .022 14.91 1.64‐59.80




Note: Number of events <5 so data not shown.
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for any cancer site observed in excess in any degree of re-
lationship, results are shown for all degrees of relationship. 
No Ewing sarcoma patients were identified among first‐, sec-
ond‐, or third‐degree relatives of Ewing sarcoma patients. The 
data indicate significantly increased risk for lung/bronchus, 
female genital, and prostate cancer in first‐degree relatives. 
Significantly increased risks were observed in second‐degree 
relatives for breast cancer, nonmelanoma eye cancer, ma-
lignant peripheral nerve sheath cancer, non‐Hodgkin lym-
phoma, and translocation sarcomas. Significantly increased 
risk for stomach cancer, prostate cancer, and acute lympho-
cytic leukemia was observed in third‐degree relatives. Small 
sample sizes may have limited this analysis, but some consis-
tency can be observed. Non‐Hodgkin lymphoma and prostate 
T A B L E  2  Estimated RRs for cancers of other sites observed in significant excess among first‐, second‐, and third‐degree relatives of 
individuals diagnosed with Ewing sarcoma
Cancer site Obs/Exp P‐value RR One‐sided 95% CI
Ewing sarcoma first‐degree relatives (n = 744)        
Breast 6/8.0 .32 0.75 0.00‐1.48
Nonmelanoma eye 0/0 .94 —  
Non‐Hodgkin lymphoma ** .43 1.78 0.09‐9.90
Lung/bronchus 7/2.8 .023 2.53 1.19‐5.21
Female genital ** .045 5.97 1.06‐21.55
Stomach ** .44 1.73 0.09‐9.66
Prostate 16/8.7 .017 1.84 1.15‐2.99
Translocation sarcoma 0/0.2 .86 —  
Malignant peripheral nerve sheath ** .05 18.52 0.95‐103.19
Acute lymphocytic leukemia ** .28 3.04 0.16‐16.95
Brain ** .09 2.92 0.60‐8.52
Ewing sarcoma Second‐degree relatives (n = 2228)        
Breast 44/29.1 .006 1.51 1.16‐2.03
Nonmelanoma eye ** .019 9.47 1.68‐34.20
Non‐Hodgkin lymphoma 16/7.8 .01 2.06 1.29‐3.35
Lung/bronchus 9/11.9 .26 0.76 0.00‐1.32
Female genital ** .66 0.82 0.00‐3.91
Stomach ** .21 0.34 0.00‐1.60
Prostate 42/34.7 .13 1.21 0.92‐1.63
Translocation sarcoma ** .039 6.61 1.16‐23.51
Malignant peripheral nerve sheath ** .009 14.59 2.59‐52.71
Acute lymphocytic leukemia 0/0.8 .45 —  
Brain 6/2.92 .08 2.06 0.75‐4.47
Ewing sarcoma third‐degree relatives (n = 6552)        
Breast 72/74.4 .42 0.97 0.00‐1.18
Nonmelanoma eye ** .42 1.83 0.09‐10.21
Non‐Hodgkin lymphoma 37/33.3 .29 1.11 0.83‐1.53
Lung/bronchus 29/32.1 .33 0.9 0.00‐1.23
Female genital ** .38 0.62 0.00‐1.96
Stomach 16/9.3 .029 1.71 1.08‐2.78
Prostate 117/95.3 .017 1.23 1.05‐1.47
Translocation sarcoma 0/0.8 .47 —  
Malignant peripheral nerve sheath 0/0.4 .69 —  
Acute lymphocytic leukemia 7/2.0 .005 3.46 1.62‐7.11
Brain   12/7.2 1.66 0.86‐2.91
**<5 patients observed; data not shown. 
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cancer were observed in excess in all degrees of relationship, 
although the excess was not always statistically significant. 
Similarly, acute lymphoblastic leukemia and malignant pe-
ripheral nerve sheath cancers were observed in excess in two 
of the three degrees of relationship, although not always with 
statistical significance. Conversely, the significant excesses 
observed for lung/bronchus and female genital cancers in 
first‐degree relatives were not observed in excess in the other 
degrees of relationship, suggesting the likelihood of common 
environmental effects or multiple testing issues.
4 |  DISCUSSION
We previously reviewed the evidence of a heritable predis-
position for Ewing sarcoma and concluded that more data 
were needed in the field.26 This analysis of risk of cancer 
for other sites among Ewing sarcoma patients and their rela-
tives in a unique genealogical resource indicates evidence for 
some increased cancer predisposition in this population. The 
observation of coaggregation of cancer of different sites in 
Ewing sarcoma patients and in their relatives could provide 
evidence for shared genetic etiology, and thereby enhance 
knowledge of cancer predisposition. Although sample sizes 
for this and previous studies remain relatively small, over-
lap exists with previously reported findings with respect to 
increased risk for stomach cancer, and several novel observa-
tions have been made.
Significantly elevated HRs for cancers of several other 
sites were observed for Ewing sarcoma patients (Table 1). 
Secondary malignant neoplasms are known to be associated 
with Ewing sarcoma; however, the degree to which therapy 
contributes to this risk is difficult to determine.27-29 Breast 
cancer has previously been reported as one such secondary 
malignant neoplasm seen in excess among Ewing sarcoma 
patients.30,31 While some of this risk is likely attributed to 
radiation fields in the chest area, increased risk in the absence 
of radiation to the chest area has also been demonstrated. A 
recent report shows that the EWS‐FLI1 transcription causes 
R‐loops and blocks BRCA1 repair in Ewing sarcoma, perhaps 
explaining the observed increased risk of breast cancer.32 
Our study identified excess breast cancer risk in Ewing sar-
coma patients (Table 1) and in their second‐degree relatives 
(Table 2), further supporting the hypothesis of an associated 
inherited risk for breast cancer. It is possible that increased 
screening in Ewing sarcoma patients and their relatives might 
partially explain observed excesses.
Literature noting brain cancer as a secondary malignant 
neoplasm in Ewing sarcoma is less complete. Similar to 
breast cancer, brain cancer was seen in excess in not only 
Ewing sarcoma patients (Table 1), but in their first‐degree rel-
atives as well (Table 2); and was observed to be elevated, but 
not statistically significantly so, in second‐ and third‐degree 
relatives. This suggests a potential inherited predisposition 
for both breast and brain cancer, as increased risk in relatives 
of Ewing sarcoma patients cannot be attributed to secondary 
malignancies related to treatment of Ewing sarcoma. These 
results are based on small sample sizes, but the lower limit 
of the confidence intervals for the significantly elevated HRs 
(ranging from 1.77 to 23.06) as well as the excess risk ob-
served in relatives indicate that some special attention to risk 
for these other cancers occurring among Ewing sarcoma pa-
tients and their relatives might be warranted.
Results for risk of cancers of other sites in both the close 
and distant relatives of Ewing sarcoma patients identified 
some other cancer sites of interest. Prostate cancers were ob-
served in excess among first‐ and third‐degree relatives. This 
seems especially relevant to Ewing sarcoma as prostate can-
cers frequently harbor ETS gene fusions.33,34 Whether a com-
mon risk factor may contribute to such aberrant ETS gene 
fusions remains unknown, but this observation provides one 
potential link between Ewing sarcoma and prostate cancer 
etiology. Again, sample sizes are small, and additional stud-
ies could clarify these results.
Differences from other investigations on the risk of cancer 
in Ewing sarcoma patients and their relatives include the use 
of genealogic data to define relationships and the use of an 
NCI SEER cancer registry for cancer diagnosis, in contrast 
to other studies' reliance on self‐reported family history and 
cancer status. It must be noted that after an appropriate cor-
rection for multiple testing for the 37 cancer sites examined in 
three degrees of relationship, none of the observed excesses 
remain statistically significant.
Limitations of this study include the small number of 
Ewing sarcoma patients with adequate genealogy data 
(n = 143). Complete Utah cancer data are only available from 
1973, providing a small window of diagnoses that does not 
allow complete consideration of relatives born in different 
generations. Cancers occurring outside the state of Utah are 
also censored. Missing or incorrect genealogy data are possi-
ble; genealogy data does not always represent biological re-
lationships. The Utah population analyzed is almost entirely 
of Northern European ancestry, so findings should not be 
extrapolated further. Strengths of this study include that all 
UCR cancer patients have pathologic confirmation and are 
carefully vetted, and while some diagnoses and relationships 
may have been censored, the results are unbiased.
This study suggests that other cancers may be observed in 
excess in Ewing sarcoma patients and their relatives. Some 
of the cancers identified in excess here are recognized to be 
associated with the known cancer genes reported to be ob-
served in 11% of Ewing sarcoma patients (TP53, RET, and 
PMS2); a search for pathogenic variants in some of the pa-
tients and relatives identified in this study could clarify this. 
Identifying and validating these cancers that are consistently 
seen in excess in Ewing sarcoma patients and their relatives 
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could aid in narrowing down genetic risk if a common and 
overlapping risk mechanism is responsible. Furthermore, if 
validated, this information could be used to reduce the risk 
of increased secondary malignancies in Ewing sarcoma, and 
also to design early tumor surveillance strategies. Similar to 
many other Ewing sarcoma studies, despite the use of the 
UPDB, our investigation was still limited in statistical power 
by sample size. Follow‐up studies with a focus on cancer his-
tory in Ewing sarcoma probands and their relatives would re-
inforce these findings and give more weight to clinical action 
based on the excess tumors identified in patients and families 
with Ewing sarcoma.
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